Wu Jo-Hsuan, Jerng Jih-Shuin, Su Chien-Chia
National Taiwan University College of Medicine, Taipei, Taiwan.
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
BMJ Case Rep. 2019 Apr 4;12(4):e229343. doi: 10.1136/bcr-2019-229343.
Carteolol, a non-selective beta-antagonist with a potential risk of severe bronchial constriction in patients with asthma, is one of the most commonly prescribed medication for managing ocular pressure in glaucoma. We present a case of a 24-year-old woman with a history of atopy but no known asthma who presented an insidious onset of clinical manifestations compatible with drug-induced asthma after the initiation of carteolol for ocular hypertension control. The patient developed progressive chest tightness and dyspnoea for 2 months before the pulmonary function test revealed a positive bronchoprovocation response. She reported significant improvement of respiratory symptoms within 2 weeks after the discontinuation of carteolol, and a negative provocation response was later confirmed by repeat pulmonary function test. In conclusion, eye drops with non-selective beta-antagonising effect can induce asthmatic symptoms in patients without a previous diagnosis of asthma and should be administered with caution in patients with associated risk factors.
卡替洛尔是一种非选择性β受体拮抗剂,对哮喘患者有严重支气管收缩的潜在风险,是青光眼治疗中最常用的控制眼压的药物之一。我们报告一例24岁女性病例,该患者有特应性病史但无已知哮喘,在开始使用卡替洛尔控制眼压后,出现了与药物性哮喘相符的隐匿性临床表现。患者在肺功能测试显示支气管激发试验阳性前2个月出现进行性胸闷和呼吸困难。她报告在停用卡替洛尔后2周内呼吸道症状有显著改善,随后重复肺功能测试证实激发试验结果为阴性。总之,具有非选择性β受体拮抗作用的眼药水可在既往无哮喘诊断的患者中诱发哮喘症状,在有相关危险因素的患者中应谨慎使用。